IpiNovyx Logo.jpg
IpiNovyx Bio Closes $10 Million Seed Financing to Advance Best-in-Class Immunoproteasome Inhibitors Toward First-in-Human Clinical Studies
October 05, 2021 07:00 ET | IpiNovyx
Participating Investors include Viva BioInnovator, Eli Lilly and Company, Opaleye Management, Orange Grove Bio and Alexandria Venture Investments Foundational Science Stems From Landmark Research at...
logo-alt.png
Global Schizophrenia Drug Market is estimated to be US$ 9.8 Bn by 2030 with a CAGR of 2.7% during the forecast period - by PMI
February 24, 2021 10:05 ET | PMI
Covina CA, Feb. 24, 2021 (GLOBE NEWSWIRE) -- The global schizophrenia drug market accounted for US$ 7.5 Bn in 2020 and is estimated to be US$ 9.8 Bn by 2030 and is anticipated to register a CAGR of...
logo-alt.png
Global Diabetes Drugs Market–Analysis and Demand with Forecast Overview to 2029 - by PMI
January 12, 2021 10:05 ET | PMI
Covina, CA, Jan. 12, 2021 (GLOBE NEWSWIRE) -- The significant growth in the market can be attributed to factors, such as the rising prevalence of diabetes and the increasing number of programs...
PDF to PNG Logo.png
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Prevail Therapeutics Inc. Buyout
December 16, 2020 14:56 ET | Rigrodsky & Long, P.A.
WILMINGTON, Del., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Prevail Therapeutics Inc. (“Prevail”) (NASDAQ GS: PRVL) regarding possible breaches...
BES_Mark.jpg
PREVAIL THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of PRVL and Encourages Investors to Contact the Firm
December 16, 2020 12:37 ET | Bragar Eagel & Squire
NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of...
BES_Mark.jpg
ELI LILLY AND COMPANY ALERT: Bragar Eagel & Squire, P.C. is Investigating Eli Lilly and Company on Behalf of Eli Lilly Stockholders and Encourages Investors to Contact the Firm
October 20, 2020 19:00 ET | Bragar Eagel & Squire
NEW YORK, Oct. 20, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Eli Lilly and Company...
BES_Mark.jpg
ELI LILLY AND COMPANY ALERT: Bragar Eagel & Squire, P.C. is Investigating Eli Lilly and Company on Behalf of Eli Lilly Stockholders and Encourages Investors to Contact the Firm
October 15, 2020 20:00 ET | Bragar Eagel & Squire
NEW YORK, Oct. 15, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Eli Lilly and Company...
logo-alt.png
Global Rheumatoid Arthritis Therapeutics Market; High adoption of disease-modifying antirheumatic drugs (DMARDs) will boost the market - PMI
June 25, 2020 10:35 ET | PMI
Covina, CA, June 25, 2020 (GLOBE NEWSWIRE) -- The global rheumatoid arthritis therapeutics market accounted for US$ 25.7 billion in 2019 and is estimated to be US$ 39.8 billion by 2029 and is...
PMCB YT .png
World-Renowned Oncologist Bullish on Potential of PharmaCyte’s Technology, Clinical Trial in Pancreatic Cancer
January 23, 2019 09:25 ET | PharmaCyte Biotech
NEW YORK, NY, Jan. 23, 2019 (GLOBE NEWSWIRE) -- With PharmaCyte Biotech, Inc.’s (OTCQB: PMCB) naming of Medpace, Inc., a global full-service clinical contract research organization (CRO) to conduct...
Endocrinologist & Researcher Dr. Dara P. Schuster Named CEO of T1D Exchange
June 22, 2018 08:00 ET | T1D Exchange
BOSTON, June 22, 2018 (GLOBE NEWSWIRE) -- T1D Exchange, a patient-centered research organization dedicated to accelerating therapies and improving care for people with type 1 diabetes (T1D), today...